

NCT ID	NCT06066424
Title	Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
Phase	Phase 1
Date Added	2023-10-04
Location	Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Cyclophosphamide, Fludarabine Phosphate, Rimiducid, TROP2-CAR-NK Cells
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06065371
Title	Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Phase	Phase 1
Date Added	2023-10-03
Location	Michigan, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	capecitabine, Sacituzumab govitecan
Tags	MSS/ MMRp
NCT ID	NCT06060704
Title	Envafolelimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
Phase	Phase 2
Date Added	2023-09-29
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Bevacizumab, Envafolelimab, Trifluridine/Tipiracil, Avastin, Lonsurf
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06055439
Title	A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Phase	Phase 1, Phase 2
Date Added	2023-09-26
Location	Georgia, United States Illinois, United States Pennsylvania, United States Tennessee, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06047015
Title	Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer
Phase	Phase 1

Date Added	2023-09-21
Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	
Tags	MSS/ MMRp
NCT ID	NCT06043713
Title	Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations
Phase	Phase 1
Date Added	2023-09-21
Location	Washington, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Bendamustine, Cyclophosphamide, Fludarabine
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06039202
Title	Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2023-09-15
Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	CA102N, TAS-102
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06039384
Title	A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Phase	Phase 1
Date Added	2023-09-15
Location	California, United States Colorado, United States Michigan, United States Texas, United States Virginia, United States Italy Spain United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Adagrasib, INCB099280
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06034860

Title	Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Phase	Phase 1
Date Added	2023-09-13
Location	California, United States Indiana, United States Missouri, United States New York, United States Virginia, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	MT-8421, Nivolumab, Opdivo
Tags	MSI-H/ MMRd

NCT ID	NCT06026774
Title	Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms
Phase	Phase 1
Date Added	2023-09-07
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp